Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: stock_observer_77
Search This Board: 
Last Post: 5/17/2019 2:19:53 PM - Followers: 86 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

GALT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT News: Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019 05/10/2019 08:05:00 AM
GALT News: Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) 05/10/2019 08:03:36 AM
GALT News: Current Report Filing (8-k) 05/10/2019 08:00:33 AM
GALT News: Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update 05/10/2019 08:00:00 AM
GALT News: Current Report Filing (8-k) 05/10/2019 07:56:56 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#3598   I just oversubscribed for an additional 40% above thefamilyman 05/17/19 02:19:53 PM
#3597   It was definitely wrong and corrected because I biotech2010 05/15/19 02:53:54 PM
#3596   Looks like they did have it wrong originally Phantom Lord 05/15/19 01:21:06 PM
#3595   I received an amended, corrected Rights Offer notification biotech2010 05/15/19 01:15:10 PM
#3594   STILL UNDERVALUED AT THIS PRICE microcapbiotech 05/10/19 03:17:06 PM
#3593   If I'm going to believe something it's the Phantom Lord 05/09/19 07:24:27 PM
#3592   The GALT press release clearly states that the biotech2010 05/09/19 06:58:08 PM
#3591   I can't confirm that is what Schwab sent Phantom Lord 05/09/19 05:15:01 PM
#3590   I'm not misreading anything, there is a discrepancy biotech2010 05/09/19 05:10:04 PM
#3589   You're misreading the prospectus. Phantom Lord 05/09/19 04:48:41 PM
#3588   Phantom Lord 05/09/19 04:33:46 PM
#3587   The offering I received through TD Ameritrade says jmh0602 05/09/19 03:17:46 PM
#3586   My math isn't wrong, I took what is biotech2010 05/09/19 03:04:30 PM
#3585   I believe your math is wrong. I just jmh0602 05/09/19 02:40:45 PM
#3584   Good Luck! stock_observer_77 05/09/19 09:27:57 AM
#3583   You and the rest who are participating in biotech2010 05/09/19 09:26:15 AM
#3582   That makes no sense. stock_observer_77 05/09/19 09:09:18 AM
#3581   Please send all of your money to GALT biotech2010 05/09/19 07:20:15 AM
#3580   To each his own stock_observer_77 05/09/19 04:13:57 AM
#3579   This rights offering is a joke. biotech2010 05/08/19 09:57:30 PM
#3578   BIVI >>> Clinically de-risked development program f Trend-Setter 05/02/19 12:48:19 PM
#3577   According to theory, but who really knows ? buckysherm 04/17/19 11:54:38 AM
#3576   We were at $5, The the official announcement buckysherm 04/17/19 11:53:18 AM
#3575   Looks like 2-3 years of bad road with jimmy667 04/15/19 02:23:11 PM
#3574   Right, and I would expect $3.50 if this buckysherm 04/15/19 11:52:08 AM
#3573   It has been dropping the last few days jimmy667 04/15/19 11:12:32 AM
#3572   It drops like this almost EVERY day in buckysherm 04/15/19 11:05:04 AM
#3571   SEC and FINRA rules. Call your broker. Be jimmy667 04/15/19 10:34:02 AM
#3570   I do not see the “accredited investor” requirement thefamilyman 04/13/19 03:35:59 PM
#3569   More... Q: Are there any conditions to my right to thefamilyman 04/13/19 03:02:05 PM
#3568   More... Q: How do I exercise my subscription rights if thefamilyman 04/13/19 02:57:13 PM
#3567   More... Procedure for Exercising Rights You may exercise your subscription thefamilyman 04/13/19 02:50:09 PM
#3566   Offering Summary Securities Offered We are distributing to you, at thefamilyman 04/13/19 02:46:25 PM
#3565   I am not seeing the accredited investor requirement thefamilyman 04/13/19 02:44:11 PM
#3564   LOL! Funnyman for Familyman and bull short for thefamilyman 04/13/19 02:33:32 PM
#3563   What kind of bull short is that ? buckysherm 04/13/19 07:26:42 AM
#3562   Misprint. 52 week high is $9.49 jimmy667 04/12/19 09:37:55 PM
#3561   Need bona fide investing experience and a liquid jimmy667 04/12/19 09:35:01 PM
#3560   How does one get to be “accredited” ? buckysherm 04/12/19 08:40:27 PM
#3559   The 52 Week High is shown as 499 buckysherm 04/12/19 08:36:19 PM
#3558   LOL! And thanks for both responses. thefamilyman 04/12/19 04:16:55 PM
#3557   If you are retail in this stock you jimmy667 04/12/19 09:11:15 AM
#3556   Ok funnyman it is not an app it jimmy667 04/11/19 11:39:27 PM
#3555   How do I access the app? thefamilyman 04/11/19 01:23:31 PM
#3554   They turned on the financing app with the jimmy667 04/11/19 11:19:58 AM
#3553   Hello ? < tap tap > Is this buckysherm 04/11/19 10:47:01 AM
#3552   The lack of cash and mgmt failure to Amatuer17 03/24/19 07:57:07 PM
#3551   GALT is the last man standing in this Chess Master 03/24/19 02:24:36 PM
#3550   Is WS and BP smart enough to act buckysherm 03/23/19 10:59:00 AM
#3549   GILD failed - CNAT failed Who is remaining now Amatuer17 03/22/19 11:51:51 AM
PostSubject